The goal of treating patients with atrial fibrillation is to decrease symptoms and prevent complications, especially stroke. All patients should be evaluated for their risk of stroke and blood clots.

Symptoms 
  • Symptom of atrial fibrillation.
  • Fatigue: Feeling tired or weak, even with normal activities.
  • Shortness of breath: Difficulty breathing or feeling like you can’t catch your breath, especially during physical activity.
  • Dizziness or lightheadedness: Feeling faint or dizzy, which can occur when the heart is beating irregularly.
  • Chest pain or discomfort: A sensation of pressure or tightness in the chest, which can occur in some cases of atrial fibrillation.
  • Confusion or memory problems: Difficulty focusing or thinking clearly, which can occur when the brain is not getting enough oxygen-rich blood due to the irregular heartbeat.


Types of AF
  •  Paroxysmal symptoms stop within 48 hours without treatment (patients with symptomatic infrequent episodes “pill-in pocket” management can be used using flecainide, beta blocker or a calcium channel blocker. 
  • Persistent AF: Episodes last longer than a week
  • Permanent AF: Longterm condition 
management

There are two main ways to manage atrial fibrillation:

  • Controlling the heart rate (rate control)- arrhythmia less than 48 hours or
  • Trying to restore and maintain a regular heart rhythm (rhythm control)- arrhythmia longer than 48 hours 

If initial treatment is not effective, patients should be referred for specialised care within four weeks. In cases where medication does not work or is not appropriate, ablation procedures can be considered.


Stroke risk 

Tool used to assess stroke risk and bleeding risk 

  • Stroke risk: CHA2DS2- VASc (factors used age, sex, and prior history of congestive heart failure, hypertension, stroke, transient ischaemic attacks (TIA), thromboembolic events, vascular disease, or diabetes mellitus.


  • Bleeding risk: ORBIT 


Acute Presentation

Life threatening haemodynamic instability: Electrical cardioversion and anticoagulation

Non- life threatening 
haemodynamic instability:

Less than 48 hours: Rate or rhythm control (rhythm control using cardioversion–> electrical or pharmacological i.e. flecainide or amiodarone)

More than 48 hours: Rate control (if urgent IV beta blocker or verapamil if (LVEF) is ≥40%






Cardioversion

Rhythm control is by using cardioversion

Cardioversion: Electrical or pharmacological.

Cannot give if more than 48 hours (electrical is preferred if more than 48 hours) but should be delayed until the patient is fully anticoagulated for at least 3. Parenteral anticoagulation (heparin) can be started if this is not possible once a left atrial thrombus has been ruled out.

Oral anticoagulation to be given for 4 weeks after

Maintenance

Rate control: First line method

Ventricular rate control using beta-blocker (not sotalol hydrochloride), or with a rate-limiting calcium channel blocker such as diltiazem hydrochloride [unlicensed indication] or verapamil hydrochloride as monotherapy.

Mono-therapy fails: consider dual therapy using either two of: beta-blocker, digoxin or diltiazem hydrochloride

If dual therapy fails: Rhythm control to be tried 

If LVEF is <40% the combination of a beta-blocker (licensed for use in heart failure) and digoxin should be considered (digoxin preferred if the person has congested heart failure and AF. 

Rhythm control: Second line method

Using beta blockers (not sotalol) as first line

Using anti-arrhythmic drug (such as amiodarone hydrochloride, flecainide acetate, propafenone hydrochloride, or sotalol hydrochloride)





 

Stroke Risk 

Patients with atrial fibrillation should be assessed for their risk of stroke using the CHA2DS2-VASc risk tool and the need for thromboprophylaxis.

Offer anticoagulation to those with:

CHA2DS2-VASc score of 2 or above

Men with a CHA2DS2-VASc score of 1.

Direct-acting oral anticoagulants are recommended for non-valvular atrial fibrillation.

In non-valvular AF DOACs such as apixaban, dabigatran, edoxaban, or rivaroxaban, is recommended If contra-indicated or unsuitable a vitamin K antagonist such as warfarin sodium can be used.

Parenteral anticoagulation (heparin) should be offered to patients with new-onset atrial fibrillation who are receiving subtherapeutic or no anticoagulation therapy

Aspirin monotherapy is not recommended for stroke prevention in patients with atrial fibrillation.